CSPC Innovation Subsidiary Initiates Phase Ib/II Clinical Trial for SYS6090

Stock News08-19

Cspc Innovation Pharmaceutical Co., Ltd. (300765.SZ) has announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., recently kicked off a Phase Ib/II clinical trial designated SYS6090-007. The study is designed to evaluate the safety, tolerability, and efficacy of the SYS6090 injection when used in combination therapy for patients with hepatocellular carcinoma.

The newly initiated SYS6090-007 trial is an open-label, multicenter Phase Ib/II study, specifically aimed at assessing the safety, tolerability, and effectiveness of the SYS6090 injection combination regimen in participants with hepatocellular carcinoma. Based on the results of this study, the company plans to advance the combination therapy into a Phase III clinical trial to further verify the drug's efficacy and safety profile in this patient population. Currently, participant recruitment and screening for the SYS6090-007 study are progressing actively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169059614?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-19 16:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169059614","market":"sh","top_or_hot":-1,"title":"CSPC Innovation Subsidiary Initiates Phase Ib/II Clinical Trial for SYS6090","media":"Stock News","content":"<p><b>Cspc Innovation Pharmaceutical Co., Ltd.</b> (300765.SZ) has announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., recently kicked off a Phase Ib/II clinical trial designated SYS6090-007. The study is designed to evaluate the safety, tolerability, and efficacy of the SYS6090 injection when used in combination therapy for patients with hepatocellular carcinoma.<br><br>The newly initiated SYS6090-007 trial is an open-label, multicenter Phase Ib/II study, specifically aimed at assessing the safety, tolerability, and effectiveness of the SYS6090 injection combination regimen in participants with hepatocellular carcinoma. Based on the results of this study, the company plans to advance the combination therapy into a Phase III clinical trial to further verify the drug's efficacy and safety profile in this patient population. Currently, participant recruitment and screening for the SYS6090-007 study are progressing actively.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Innovation Subsidiary Initiates Phase Ib/II Clinical Trial for SYS6090</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Innovation Subsidiary Initiates Phase Ib/II Clinical Trial for SYS6090\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-19 16:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Cspc Innovation Pharmaceutical Co., Ltd.</b> (300765.SZ) has announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., recently kicked off a Phase Ib/II clinical trial designated SYS6090-007. The study is designed to evaluate the safety, tolerability, and efficacy of the SYS6090 injection when used in combination therapy for patients with hepatocellular carcinoma.<br><br>The newly initiated SYS6090-007 trial is an open-label, multicenter Phase Ib/II study, specifically aimed at assessing the safety, tolerability, and effectiveness of the SYS6090 injection combination regimen in participants with hepatocellular carcinoma. Based on the results of this study, the company plans to advance the combination therapy into a Phase III clinical trial to further verify the drug's efficacy and safety profile in this patient population. Currently, participant recruitment and screening for the SYS6090-007 study are progressing actively.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSYK","symbol_name":"PSYK ETF","start_time":0,"source_url":"","article_id":"1169059614","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169059614","pubTimestamp":1787126666,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Cspc Innovation Pharmaceutical Co., Ltd. (300765.SZ) has announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., recently kicked off a Phase Ib/II clinical trial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300765":"石药创新","PSYK":"PSYK ETF","BMED":"iShares Health Innovation Active ETF","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK0226":"食品制造","MDTX":"Corgi MediaTek 2x Daily ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF"},"translate_title":"石药集团创新子公司启动SYS6090 Ib/II期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300765":1,"IBBJ":1,"PSYK":1,"IBBQ":1,"MDTX":1,"BMED":1},"content_text":"Cspc Innovation Pharmaceutical Co., Ltd. (300765.SZ) has announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., recently kicked off a Phase Ib/II clinical trial designated SYS6090-007. The study is designed to evaluate the safety, tolerability, and efficacy of the SYS6090 injection when used in combination therapy for patients with hepatocellular carcinoma.The newly initiated SYS6090-007 trial is an open-label, multicenter Phase Ib/II study, specifically aimed at assessing the safety, tolerability, and effectiveness of the SYS6090 injection combination regimen in participants with hepatocellular carcinoma. Based on the results of this study, the company plans to advance the combination therapy into a Phase III clinical trial to further verify the drug's efficacy and safety profile in this patient population. Currently, participant recruitment and screening for the SYS6090-007 study are progressing actively.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169059614","isCrawlerRequest":true}